Home>Topics>Stocks>Endo Pharmaceutical Holdings

Endo Pharmaceutical Holdings ENDP

  1. All
  2. Commentary
  3. Headlines
    1. Health Care: 3 Picks in a More Expensive Sector

      Headlines

      Wed, 1 Apr 2015

      Allergan by Actavis. This trend is also evident with Valeant 's VRX bid for Salix (which may subsequently get outbid by Endo ENDP ). Further, AbbVie 's ABBV bid for Pharmacyclics PCYC also shows the strong need by AbbVie to redeploy capital to secure growth

    2. Actavis' Wide-Moat Transformation Offers Shareholder Rewards

      Headlines

      Mon, 23 Mar 2015

      Department rules may dissuade future tax inversions, we think established tax inverters, such as Actavis, Valeant, and Endo ENDP , are best positioned, especially since any retroactive penalties seem highly unlikely. Actavis' rapid acquisition pace will

    3. The Market: Exaggerated Woes

      Headlines

      Tue, 14 Oct 2014

      Endo Pharmaceuticals ENDP announced July 11 that it no longer expects to file a new drug application for its ketoprofen pain-relief patch by the first

    4. Credit Market Outlook: Tight Spreads Will Keep a Lid on Returns

      Headlines

      Thu, 26 Jun 2014

      to pursue acquisitions that boost their currently lackluster growth prospects. While Teva TEVA "> TEVA and Endo 's ENDP "> ENDP notes appear to compensate investors for that event risk, Mylan 's MYL "> MYL notes do not, which keeps it on our

    5. Our Outlook for the Credit Markets

      Headlines

      Fri, 27 Dec 2013

      narrow moat) has steadily reduced its debt such that leverage has declined to 1.2 times from 2 times. Endo Health Solutions ENDP (rating: BB, narrow moat) has announced that it is using equity to fund an acquisition, which will help the firm diversify

    6. Endo's New CEO Shakes Up Firm With Restructuring Plan and Management Changes

      Commentary

      Thu, 6 Jun 2013

      After just three months on the job, Endo Health Solutions ENDP CEO Rajiv De Silva announced that he is spearheading a major restructuring effort at the specialty health-care company. This

    7. Strong Generic Performance Offsets Weak Branded Sales in Endo's In-Line 1Q

      Commentary

      Tue, 7 May 2013

      Endo Health Solutions ENDP reported first-quarter results that met our expectations for increased competition in its core branded pharmaceutical division

    8. Endo Ekes Out Earnings Growth in 2012; Generic Entrants to Cause Sales and Earnings Declines in 2013

      Commentary

      Fri, 1 Mar 2013

      Endo ENDP reported net revenue of USD 3.03 billion and USD 5.02 per share in earnings for the year, at the bottom end of its prior guidance

    9. Endo Under Review Following News of CEO's Departure and Earnings Miss

      Commentary

      Thu, 13 Dec 2012

      We are putting Endo Health Solutions ENDP under review following its announcement that the CEO will retire in 2013 and that it does not expect to meet its previously issued

    10. Lowering Our Fair Value Estimate on Endo's Disappointing 3Q Results and Revised Full-Year Outlook

      Commentary

      Tue, 6 Nov 2012

      Endo ENDP reported disappointing third-quarter results and lowered full-year guidance that fell short of our expectations. The company

    « Prev12345Next »
    Content Partners